NCT06412198 2026-03-06
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT03994796 2026-03-04
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 2 Suspended
NCT05722327 2026-03-04
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07318389 2026-02-27
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT07382726 2026-02-20
Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT06130254 2025-10-14
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05472623 2025-09-15
Neo-Kan
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT05634525 2025-07-25
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05848843 2024-01-23
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
Phase 1 Withdrawn